(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

ELIFACIL

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

ELIFACIL

ST13

US500000097299307

Class

5

Filing

97299307

Registration

7221319

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

29

Latest update

11/21/2023

Trademark type

Word

Nice classes

5

Filing date

03/07/2022

Registration date

11/21/2023

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

11/21/2023

Last transaction

11/21/2023

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

Drawing code

4

Owner type

99

Owner location

Lund, SE

Examiner

MARTIN, LIEF

Law office

M30

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

HANSA BIOPHARMA AB

Representatives

Gregory J. Chinlund

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Pharmaceutical preparations and veterinary preparations for use in the treatment of cancerautoimmune diseasesmedical conditions arising from transplantation and gene therapyfor use with transplantation and gene therapy; pharmaceutical preparationspreparations for cleaving human antibodies; pharmaceutical preparations and veterinary preparationsenzyme preparations and sterilizing preparations; sanitary preparationschemical enzyme preparations and sterilizing preparations; medicines for diagnosingpreventingtreating cancer and autoimmune diseases for human and veterinary purposes; pharmaceutical preparations for elimination of antibodies for therapeutic purposes in immune related diseases and conditions; enzymes for medical and veterinary purposes

Publications

History of USPTO decisions and trademark events.

29 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

11/21/2023

R.PR

REGISTERED-PRINCIPAL REGISTER

11/21/2023

DP1B

1(B) BASIS DELETED; PROCEED TO REGISTRATION

10/16/2023

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

10/16/2023

IUCN

NOTICE OF ALLOWANCE CANCELLED

09/25/2023

D1BR

TEAS DELETE 1(B) BASIS RECEIVED

09/25/2023

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

07/25/2023

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

05/30/2023

PUBO

PUBLISHED FOR OPPOSITION

05/30/2023

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

05/10/2023

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

04/24/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

03/22/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

03/22/2023

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

03/21/2023

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

03/14/2023

GNRT

NON-FINAL ACTION E-MAILED

03/14/2023

CNRT

NON-FINAL ACTION WRITTEN

03/14/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

02/04/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

02/03/2023

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

02/03/2023

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

08/03/2022

GNRT

NON-FINAL ACTION E-MAILED

08/03/2022

CNRT

NON-FINAL ACTION WRITTEN

08/03/2022

DOCK

ASSIGNED TO EXAMINER

08/03/2022

AMPX

PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED

04/11/2022

ALIE

ASSIGNED TO LIE

04/07/2022

PARI

TEAS VOLUNTARY AMENDMENT RECEIVED

04/05/2022

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

03/11/2022

NWAP

NEW APPLICATION ENTERED

03/10/2022

Continuous trademark protection

Get notified about every new filing that threatens ELIFACIL or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.